Please assess the completion status of the following clinical trial:

Trial Title: Phase IIIb Study of APD421 in Combination as PONV Prophylaxis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female patients ≥ 18 years of age~* Patients undergoing elective surgery (open or laparoscopic technique) under general anaesthesia, expected to last at least one hour from induction of anaesthesia to wound closure~* Patients with at least 3 Apfel risk factors for PONV~Exclusion Criteria:~* Patients scheduled to undergo transplant surgery~* Patients scheduled to receive only a local anaesthetic/regional neuraxial (intrathecal or epidural) block~* Patients who are expected to remain ventilated for a period after surgery~* Patients who are expected to need a naso- or orogastric tube in situ after surgery is completed

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- APD421 + standard anti-emetic (Type: EXPERIMENTAL): Single dose of IV APD421
- Placebo + standard anti-emetic (Type: PLACEBO_COMPARATOR): Single dose of IV placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).